Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.

PURPOSE: Tropomyosin receptor kinase (TRK) inhibitors have emerged as a promising class of targeted therapies for patients with tumors containing neurotrophic tyrosine receptor kinase (NTRK) gene fusions. While not noted in early clinical studies, ab…

Preview only. Read the full abstract at the source